MacroGenics, Inc. (MGNX)
NASDAQ: MGNX · Real-Time Price · USD
1.710
-0.070 (-3.93%)
At close: Jul 25, 2025, 4:00 PM
1.750
+0.040 (2.34%)
After-hours: Jul 25, 2025, 7:58 PM EDT

Company Description

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.

The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials.

It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

MacroGenics, Inc.
MacroGenics logo
CountryUnited States
Founded2000
IPO DateOct 10, 2013
IndustryBiotechnology
SectorHealthcare
Employees341
CEOScott Koenig

Contact Details

Address:
9704 Medical Center Drive
Rockville, Maryland 20850
United States
Phone301 251 5172
Websitemacrogenics.com

Stock Details

Ticker SymbolMGNX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001125345
CUSIP Number556099109
ISIN NumberUS5560991094
SIC Code2834

Key Executives

NamePosition
Dr. Scott Koenig M.D., Ph.D.President, Chief Executive Officer and Director
James KarrelsSenior Vice President, Chief Financial Officer and Corporate Secretary
Dr. Stephen L. Eck M.D., Ph.D.Senior Vice President of Clinical Development and Chief Medical Officer
Eric Blasius RisserChief Operating Officer
Dr. Thomas M. Spitznagel Ph.D.Senior Vice President of Technical Operations
Dr. Ezio Bonvini M.D.Senior Vice President of Research and Chief Scientific Officer
Jeffrey Stuart Peters J.D.Senior Vice President, General Counsel and Corporate Compliance Officer
Beth SmithVice President, Controller and Treasurer

Latest SEC Filings

DateTypeTitle
Jul 17, 2025SCHEDULE 13G/AFiling
Jul 7, 2025SCHEDULE 13GFiling
Jun 13, 2025SCHEDULE 13G/AFiling
Jun 10, 20258-KCurrent Report
May 22, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 13, 20258-KCurrent Report
May 13, 202510-QQuarterly Report
Apr 17, 2025SCHEDULE 13G/AFiling
Apr 11, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material